Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up awareness of the drug among its expanded patient pool. To that end ...

Daiichi Sankyo's ADCs, particularly trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan, are showing promising results in treating various cancers, including HER2-mutated NSCLC and HER2 ...

The drug helped patients live significantly longer without their cancer progressing, compared with patients who were treated ...

Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study. Merck and Daiichi ...

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell ...

No longer a far-off futuristic idea, artificial intelligence technology has seen its popularity skyrocket in recent years. | ...

Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in ...